Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar;13(5):e6813.
doi: 10.1002/cam4.6813.

A nomogram based on TFE3 IHC results and clinical factors as a preliminary screening scheme for TFE3-rearranged renal cell carcinoma

Pengju Li  1 , Quanhui Xu  1 , Minyu Chen  1 , Jiangquan Zhu  1 , Yinghan Wang  1 , Mukhtar A Mumin  1 , Kangbo Huang  2 , Zeying Jiang  3 , Hui Liang  4 , Qiong Deng  4 , Zhu Wang  4 , Bing Liao  3 , Wenfang Chen  3 , Yun Cao  5 , Jiazheng Cao  6 , Junhang Luo  1   7
Affiliations

A nomogram based on TFE3 IHC results and clinical factors as a preliminary screening scheme for TFE3-rearranged renal cell carcinoma

Pengju Li et al. Cancer Med. 2024 Mar.

Abstract

Background: TFE3 immunohistochemistry (TFE3-IHC) is controversial in the diagnosis of TFE3-rearranged renal cell carcinoma (TFE3-rearranged RCC). This study is to investigate the accuracy and sensitivity of IHC and establish a predictive model to diagnose TFE3-rearranged RCC.

Methods: Retrospective analysis was performed by collecting IHC and fluorescence in situ hybridization (FISH) results from 228 patients. IHC results were evaluated using three scoring systems. Scoring system 1 is graded based on nuclear staining intensity, scoring system 2 is graded based on the percentage of stained tumor cell nuclei, and scoring system 3 is graded based on both the nuclear staining intensity and the percentage. We collected patients' IHC results and clinical information. Important variables were screened based on univariate logistic regression analysis. Then, independent risk factors were established through multivariate logistic regression, and a nomogram model was constructed. The model was validated in internal test set and external validation set. The receiver operating characteristic curve (ROC curve), calibration curve, and decision curve analysis (DCA) were generated to assess discriminative ability of the model.

Results: The accuracy of IHC based on three scoring systems were 0.829, 0.772, and 0.807, respectively. The model included four factors including age, gender, lymph node metastasis and IHC results. Area under the curve (AUC) values were 0.935 for the training set, 0.934 for the internal test set, 0.933 for all 228 patients, and 0.916 for the external validation set.

Conclusions: TFE3 IHC has high accuracy in the diagnosis of TFE3-rearranged RCC. Clinical information such as age and lymph node metastasis are independent risk factors, which can be used as a supplement to the results of TFE3 IHC. This study confirms the value of IHC in the diagnosis of TFE3-rearranged RCC. The accuracy of the diagnosis can be improved by incorporating IHC with other clinical risk factors.

Keywords: TFE3-rearranged renal cell carcinoma; diagnosis; fluorescence in situ hybridization; immunohistochemistry.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
A nomogram to predict TFE3‐rearranged RCC and ROC curves of the nomogram. (A) A nomogram for predicting TFE3‐rearranged RCC (B–E) ROC curves of the nomogram in the training (B), internal test (C), all patients (D) and external validation cohorts (E).
FIGURE 2
FIGURE 2
Plots of decision curve results of the nomogram. Decision curve analysis of the nomogram in in the training (A), internal test (B), all patients (C) and external validation cohorts (D).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Sidhar SK, Clark J, Gill S, et al. The t(X;1)(p11.2;q21.2) translocation in papillary renal cell carcinoma fuses a novel gene PRCC to the TFE3 transcription factor gene. Hum Mol Genet. 1996;5(9):1333‐1338. - PubMed
    1. Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE. The 2016 WHO classification of tumours of the urinary system and male genital organs‐part B: prostate and bladder tumours. Eur Urol. 2016;70(1):106‐119. - PubMed
    1. Argani P. MiT family translocation renal cell carcinoma. Semin Diagn Pathol. 2015;32(2):103‐113. - PubMed
    1. Moch H, Amin MB, Berney DM, et al. The 2022 World Health Organization classification of tumours of the urinary system and male genital organs‐part a: renal, penile, and testicular tumours. Eur Urol. 2022;82(5):458‐468. - PubMed
    1. Sukov WR, Hodge JC, Lohse CM, et al. TFE3 rearrangements in adult renal cell carcinoma: clinical and pathologic features with outcome in a large series of consecutively treated patients. Am J Surg Pathol. 2012;36(5):663‐670. - PubMed

Publication types

MeSH terms

Substances